<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="HFMD is currently treated with broad-spectrum antiviral drugs, such as" exact="ribavirin" post="[19, 20] and glucocorticoids [21, 22], which can cause"/>
 <result pre="1.17 pg/mL (IL-6), 1.17 pg/mL (IL-10) and 1.63 pg/mL (TNF-α). Anti-viral effects of" exact="ribavirin" post="and cytokines in vitro and in vivo RD cells"/>
 <result pre="96-well plates were inoculated with 102.0 TCID50 YT226R for 1 h." exact="Ribavirin" post="(20 μg) and IL-1β (1250 U), IL-6 (12.5 U), IFN-λ1 (125 ng),"/>
 <result pre="neonatal mice were i.m. challenged with 100 LD50 of YT226R." exact="Ribavirin" post="(100 μg), IL-1β (2000 U), IL-6 (1000 U), IFN-λ1 (1125 U), IFN-γ (833.25 U)"/>
 <result pre="injected 1 h after infection. At 1 dpi, the same amount of" exact="ribavirin" post="and cytokines were re-injected. The body weights, clinical scores"/>
 <result pre="negative control. In vitro and in vivo antiviral effects of" exact="ribavirin" post="and cytokines RD cells were first i.m. inoculated with"/>
 <result pre="YT226R at an MOI of 0.01, and then treated with" exact="ribavirin" post="and a cytokine panel 48 hpi. The maximum inhibition rates"/>
 <result pre="and a cytokine panel 48 hpi. The maximum inhibition rates of" exact="ribavirin" post="and different cytokines on CVA4 replication were detected by"/>
 <result pre="IFN-γ and particularly IFN-α2a had comparable anti-CVA4 effects compared with" exact="ribavirin" post="in vitro. Figure 5. Anti-CVA4 effects of ribavirin and"/>
 <result pre="compared with ribavirin in vitro. Figure 5. Anti-CVA4 effects of" exact="ribavirin" post="and cytokines in vitro. One hour after the RD"/>
 <result pre="One hour after the RD cells were challenged with YT226R," exact="ribavirin" post="and different cytokines were added, respectively. CCK8 and qRT-PCR"/>
 <result pre="and qRT-PCR were employed to determine the inhibition rates of" exact="ribavirin" post="and different cytokines on CVA4 replication (A), and the"/>
 <result pre="rate of the neonatal mice. Figure 6. Anti-CVA4 effects of" exact="ribavirin" post="and cytokines in vivo. One hour after the 3-day-old"/>
 <result pre="after the 3-day-old neonatal mice (n = 10–15) were challenged with YT226R," exact="ribavirin" post="and different cytokines were administered for the first time."/>
 <result pre="ribavirin and different cytokines were administered for the first time." exact="Ribavirin" post="and the cytokines were re-administered at 24 hpi. The body"/>
 <result pre="the IFN-γ/IL-4 ratio are likely correlated with severe pathological damages." exact="Ribavirin" post="is a hypoxanthine nucleoside analog which acts as a"/>
 <result pre="antiviral drug inducing lethal mutations during viral RNA replication [48]." exact="Ribavirin" post="inhibits EVA71 replication and reduces paralysis and mortality rates"/>
 <result pre="monitoring in chronic Hepatitis C patients treated with interferon and" exact="ribavirin" post="combination therapy. Pak J Pharm Sci. 2017;30(1):11–16.28603106 [25]HuangLM, ChiuCH,"/>
</results>
